P53 EXPRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT DIAGNOSIS AND FOLLOWING TREATMENT WITH AZACITIDINE

被引：0
|
作者：
Maung, S. [1 ]
Strahan, N. [1 ]
Desmond, R. [1 ]
McHugh, J. [1 ]
Burke, C. [1 ]
O'Loughlin, J. [2 ]
Jeffers, M. [2 ]
Enright, H. [1 ]
机构：
[1] Tallaght Hosp, Trinity Coll, Sch Med, Haematol, Dublin, Ireland
[2] Tallaght Hosp, Trinity Coll, Sch Med, Cellular Pathol, Dublin, Ireland
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1225
引用
收藏
页码：491 / 491
页数：1
相关论文
共 50 条
  • [31] Relationship of p21 Expression and p53 Mutation Status in Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Eskandari, Mohammad
    Goel, Swati
    Verma, Amit
    Albanese, Joseph
    Wang, Yanhua
    LABORATORY INVESTIGATION, 2017, 97 : 347A - 347A
  • [32] Azacitidine for Treatment of Therapy Related Myelodysplastic Syndrome
    Komrokji, Rami S.
    Al Ali, Najla H.
    Alrawi, E.
    Padron, Eric
    Perkins, Janelle
    Field, Teresa
    Lancet, Jeffrey E.
    List, Alan F.
    BLOOD, 2011, 118 (21) : 745 - 746
  • [33] Treatment outcome of 5′-azacitidine for myelodysplastic syndrome
    Kim, Y. K.
    Kim, H. J.
    Song, J. E.
    Kim, S. E.
    Ahn, J. S.
    Yang, D. H.
    Lee, J. J.
    LEUKEMIA RESEARCH, 2013, 37 : S110 - S110
  • [34] Poor Outcome of Patients With Myelodysplastic Syndrome After Azacitidine Treatment Failure
    Duong, Vu H.
    Lin, Karen
    Reljic, Tea
    Kumar, Ambuj
    Al Ali, Najla H.
    Lancet, Jeffrey E.
    List, Alan F.
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (06): : 711 - 715
  • [35] p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer
    Leonard, DGB
    Travis, LB
    Addya, K
    Dores, GM
    Holowaty, EJ
    Bergfeldt, K
    Malkin, D
    Kohler, BA
    Lynch, CF
    Wiklund, T
    Stovall, M
    Hall, P
    Pukkala, E
    Slater, DJ
    Felix, CA
    CLINICAL CANCER RESEARCH, 2002, 8 (05) : 973 - 985
  • [36] P53 germline mutations and therapy-related myelodysplastic syndrome
    Inokuchi, K
    INTERNAL MEDICINE, 2005, 44 (05) : 406 - 407
  • [37] P53 MUTATION IN THE MYELODYSPLASTIC SYNDROMES
    ADAMSON, DJA
    DAWSON, AA
    BENNETT, B
    KING, DJ
    HAITES, NE
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (01) : 61 - 66
  • [38] P53 MUTATIONS IN MYELODYSPLASTIC SYNDROMES
    LUDWIG, L
    SCHULZ, AS
    JANSSEN, JWG
    GRUNEWALD, K
    BARTRAM, CR
    LEUKEMIA, 1992, 6 (12) : 1302 - 1304
  • [39] Clinical Implications of p53 Dysfunction in Patients with Myelodysplastic Syndromes
    Riva, Elena
    Zampini, Matteo
    Alberto, Termanini
    Dall'Olio, Lorenzo
    Merlotti, Alessandra
    Kulasekararaj, Austin
    Calvi, Michela
    Di Vito, Clara
    Rahal, Daoud
    Bonometti, Arturo
    Croci, Giorgio
    Boveri, Emanuela
    Gianelli, Umberto
    Ponzoni, Maurilio
    Russo, Antonio
    Tinterri, Benedetta
    Re, Francesca
    Sauta, Elisabetta
    Saba, Elena
    Travaglino, Erica
    Ubezio, Marta
    Campagna, Alessia
    Lanino, Luca
    Maggioni, Giulia
    Tentori, Cristina Astrid
    Milanesi, Chiara
    Manes, Nicla
    D'Amico, Saverio
    Ficara, Francesca
    Crisafulli, Laura
    Mavilio, Domenico
    Lugli, Enrico
    Santoro, Armando
    Diez-Campelo, Maria
    Sanz, Guillermo
    Sole, Francesc
    Platzbecker, Uwe
    Santini, Valeria
    Kordasti, Shahram
    Fenaux, Pierre
    Haferlach, Torsten
    Remondini, Daniel
    Gastone, Castellani
    Della Porta, Matteo G.
    BLOOD, 2022, 140 : 4001 - 4004
  • [40] EXPRESSION OF P53 IN MYELODYSPLASTIC SYNDROME, JMML AND NON-NEOPLASTIC BONE MARROW FAILURES IN CHILDREN
    Dahl, C.
    Kerndrup, G. B.
    Stary, J.
    Hasle, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : S27 - S27
12345